WALTHAM, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the closing of its previously announced underwritten public offering of an aggregate of 1.725 million shares of its common stock at a public offering price of $181 per share for gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, of approximately $312.2 million, which includes the exercise in full of the underwriters’ option to purchase 225,000 additional shares. The offering of the shares is expected to result in approximately $298 million in net proceeds to Repligen after deducting underwriting discounts and commissions and other estimated offering expenses payable by Repligen.
Repligen Corporation intends to use the net proceeds from this offering for working capital and other general corporate purposes. Net proceeds from this offering may also be used to fund possible acquisitions of, or investments in, complementary businesses, products, services and technologies. Repligen has not entered into any agreements or commitments with respect to any acquisitions or investments at this time.
J.P. Morgan Securities LLC and Stifel, Nicolaus & Company, Incorporated acted as joint book-running managers for the offering. Craig-Hallum Capital Group, Stephens Inc., SVB Leerink LLC and William Blair & Company, L.L.C. acted as co-managers for the offering.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located in the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden.
